Sertraline

• 

  Subject Areas on Research

  • 24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS). 
  • A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. 
  • A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. 
  • A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. 
  • A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. 
  • A probabilistic and individualized approach for predicting treatment gains: an extension and application to anxiety disordered youth. 
  • A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. 
  • Advances in Pharmacotherapy of Late-Life Depression. 
  • An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. 
  • An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials. 
  • An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. 
  • Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report. 
  • Anxiety Disorders in Caucasian and African American Children: A Comparison of Clinical Characteristics, Treatment Process Variables, and Treatment Outcomes. 
  • Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study. 
  • Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. 
  • Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. 
  • Benefits of child-focused anxiety treatments for parents and family functioning. 
  • Bupropion sustained release: a therapeutic overview. 
  • Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 
  • Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). 
  • Characterizing the effects of sertraline in post-traumatic stress disorder. 
  • Child/Adolescent anxiety multimodal study: evaluating safety. 
  • Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. 
  • Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. 
  • Cognitive improvement following treatment in late-life depression: relationship to vascular risk and age of onset. 
  • Comparison of brain structural variables, neuropsychological factors, and treatment outcome in early-onset versus late-onset late-life depression. 
  • Continued cognitive-behavior therapy versus sertraline for children and adolescents with obsessive-compulsive disorder that were non-responders to cognitive-behavior therapy: a randomized controlled trial. 
  • Data driven clusters derived from resting state functional connectivity: Findings from the EMBARC study. 
  • Davidson Trauma Scale (DTS): normative scores in the general population and effect sizes in placebo-controlled SSRI trials. 
  • Defining treatment response and remission in child anxiety: signal detection analysis using the pediatric anxiety rating scale. 
  • Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. 
  • Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. 
  • Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. 
  • Designing a pilot sequential multiple assignment randomized trial for developing an adaptive treatment strategy. 
  • Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. 
  • Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? 
  • Does antidepressant therapy improve cognition in elderly depressed patients? 
  • Does pretreatment anxiety predict response to either bupropion SR or sertraline? 
  • Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. 
  • Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. 
  • Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. 
  • Effects of Exercise and Sertraline on Measures of Coronary Heart Disease Risk in Patients With Major Depression: Results From the SMILE-II Randomized Clinical Trial. 
  • Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES). 
  • Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study. 
  • Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. 
  • Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. 
  • Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. The ENRICHD investigators. 
  • Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. 
  • Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. 
  • Exercise and pharmacotherapy in the treatment of major depressive disorder. 
  • Exercise fails to improve neurocognition in depressed middle-aged and older adults. 
  • Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. 
  • Exposure to SSRI-type antidepressants increases righting time in the marine snail Ilyanassa obsoleta. 
  • Frontal white matter anisotropy and antidepressant remission in late-life depression. 
  • Functional connectivity predictors of acute depression treatment outcome. 
  • Health status and depression remission in patients with chronic heart failure: patient-reported outcomes from the SADHART-CHF trial. 
  • High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. 
  • Impact of sleep complaints and depression outcomes among participants in the standard medical intervention and long-term exercise study of exercise and pharmacotherapy for depression. 
  • Impact of treatment improvement on long-term anxiety: Results from CAMS and CAMELS. 
  • Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report. 
  • Improvement of anger at one week predicts the effects of sertraline and placebo in PTSD. 
  • Increase in work productivity of depressed individuals with improvement in depressive symptom severity. 
  • Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression. 
  • Increased ventromedial prefrontal cortex activity and connectivity predict poor sertraline treatment outcome in late-life depression. 
  • Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study. 
  • Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. 
  • Insight and treatment outcome in obsessive-compulsive disorder. 
  • International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. 
  • Lessons from SADHART, ENRICHD, and other trials. 
  • Long-term Service Use Among Youths Previously Treated for Anxiety Disorder. 
  • MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression. 
  • Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. 
  • Mediators of change in the Child/Adolescent Anxiety Multimodal Treatment Study. 
  • Mediators of youth anxiety outcomes 3 to 12 years after treatment. 
  • Medication optimization during clozapine treatment. 
  • Multi-informant Expectancies and Treatment Outcomes for Anxiety in Youth. 
  • Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. 
  • Multidimensional effects of sertraline in social anxiety disorder. 
  • One-year change in anterior cingulate cortex white matter microstructure: relationship with late-life depression outcomes. 
  • Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. 
  • Parental anxiety as a predictor of medication and CBT response for anxious youth. 
  • Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. 
  • Pharmacogenetics studies in STAR*D: strengths, limitations, and results. 
  • Pharmacologic treatment of acute and chronic stress following trauma: 2006. 
  • Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. 
  • Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. 
  • Pharmacotherapy of social anxiety disorder: what does the evidence tell us? 
  • Placebo Response in Pediatric Anxiety Disorders: Results from the Child/Adolescent Anxiety Multimodal Study. 
  • Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. 
  • Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. 
  • Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive disorder. 
  • Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. 
  • Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. 
  • Prediction of nonremission to antidepressant therapy using diffusion tensor imaging. 
  • Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I). 
  • Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial. 
  • Presence of neuroticism and antidepressant remission rates in late-life depression: results from the Neurobiology of Late-Life Depression (NBOLD) study. 
  • Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. 
  • Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. 
  • Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis. 
  • Psychiatric sequelae of traumatic brain injury: a case report. 
  • Psychosocial treatment within sex by ethnicity subgroups in the Enhancing Recovery in Coronary Heart Disease clinical trial. 
  • QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. 
  • Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. 
  • Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. 
  • Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). 
  • Relapse of depressive symptoms after discontinuing sertraline. 
  • Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. 
  • Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. 
  • Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale. 
  • Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. 
  • Response inhibition predicts poor antidepressant treatment response in very old depressed patients. 
  • Results From the Child/Adolescent Anxiety Multimodal Extended Long-Term Study (CAMELS): Primary Anxiety Outcomes. 
  • Results from the Child/Adolescent Anxiety Multimodal Longitudinal Study (CAMELS): Functional outcomes. 
  • Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. 
  • Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. 
  • Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. 
  • Sertraline Pediatric Registry for the Evaluation of Safety: Design and Clinical Characteristics of Pediatric Patients Prescribed Sertraline. 
  • Sertraline and the Cheshire cat in geriatric depression. 
  • Sertraline as a first-line treatment for cholestatic pruritus. 
  • Sertraline attenuates hyperphagia in rats following nicotine withdrawal. 
  • Sertraline for treatment of depression in acute coronary syndromes. 
  • Sertraline in children and adolescents with social anxiety disorder: an open trial. 
  • Sertraline treatment of major depression in patients with acute MI or unstable angina. 
  • Sertraline versus imipramine to prevent relapse in chronic depression. 
  • Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. 
  • Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial. 
  • Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. 
  • Sleep-Related Problems and the Effects of Anxiety Treatment in Children and Adolescents. 
  • Somatic complaints in anxious youth. 
  • Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort. 
  • Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. 
  • Symptom-specific effects of cognitive-behavioral therapy, sertraline, and their combination in a large randomized controlled trial of pediatric anxiety disorders. 
  • The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. 
  • The Effects of Youth Anxiety Treatment on School Impairment: Differential Outcomes Across CBT, Sertraline, and their Combination. 
  • The Impact of Treatment Expectations on Exposure Process and Treatment Outcome in Childhood Anxiety Disorders. 
  • The impact of neuropsychological functioning on treatment outcome in pediatric obsessive-compulsive disorder. 
  • The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study. 
  • The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients. 
  • The role of comorbid anxiety in exercise and depression trials: Secondary analysis of the SMILE-II randomized clinical trial. 
  • The therapeutic relationship in cognitive-behavioral therapy and pharmacotherapy for anxious youth. 
  • The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. 
  • The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. 
  • The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. 
  • The undertreatment of dysthymia. 
  • Therapist-Reported Features of Exposure Tasks That Predict Differential Treatment Outcomes for Youth With Anxiety. 
  • Tics Moderate Sertraline, but Not Cognitive-Behavior Therapy Response in Pediatric Obsessive-Compulsive Disorder Patients Who Do Not Respond to Cognitive-Behavior Therapy. 
  • Trajectories of change in youth anxiety during cognitive-behavior therapy. 
  • Trajectory classes of depression in a randomized depression trial of heart failure patients: a reanalysis of the SADHART-CHF trial. 
  • Trauma, resilience and saliostasis: effects of treatment in post-traumatic stress disorder. 
  • Treatment course with antidepressant therapy in late-life depression. 
  • Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. 
  • Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study--rationale, design, and methodological issues. 
  • Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. 
  • What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology